Skip to content
value.today

Telesis Bio Inc.

Total raised
$28 M
1 round on record
Latest round
$28 M
Jun 2023
First round on record
Jun 2023
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Telesis Bio Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2023$28 MNo. 1$10 to $50 million

Telesis Bio Inc.: Raise no. 1, Jun 2023

Investors in this round

4 investors had bought by the notice of Jun 20, 2023: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Telesis Bio Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $74 M offered; $46 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
$850,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel G. Gibson · Executive Officer
  • Eric H. Esser · Executive Officer
  • Robert H. Cutler · Executive Officer
  • Todd R. Nelson · Executive Officer, Director
  • Andrea L. Jackson · Director
  • Annette V. Tumolo · Director
  • Christine A. Tsingos · Director
  • Franklin R. Witney · Director · Chair of the Board of Directors
  • Jami A. Nachtsheim · Director
  • Paul V. Meister · Director
  • William F. Snider · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, MD, NH

Remarks in the notice

  • On the amounts: “$46,200,000 common stock available for issuance upon exercise of Common Stock Warrant”

Signed by Todd R. Nelson, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 20, 2023. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Telesis Bio Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Jun 2023).

    SEC Form D (revenue range) · Jun 2023

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jun 2023

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Telesis Bio Inc.
InvestorKindAmountRoundRoleSource
BroadOak Fund IV, LLCFund or asset managernot statednot statedHeld Series A, A-1 and Z preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Danaher Corp /de/Companynot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Danaher Innovation Center LLCOthernot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GATTACA Mining LLCOthernot statednot statedHeld Series Z preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Northpond Ventures GP, LLCVenture capitalnot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Northpond Ventures, LPVenture capitalnot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Novalis LifeSciences Investments II GP, LLCFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Novalis LifeSciences Investments II, L.P.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Todd Robert NelsonPersonnot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 4 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Telesis Bio Inc.
NameRoleNamed in
Daniel G. GibsonExecutive officerJun 2023
Eric H. EsserExecutive officerJun 2023
Robert H. CutlerExecutive officerJun 2023
Todd R. NelsonExecutive officerJun 2023
Andrea L. JacksonDirectorJun 2023
Annette V. TumoloDirectorJun 2023
Christine A. TsingosDirectorJun 2023
Franklin R. WitneyChair of the Board of DirectorsJun 2023
Jami A. NachtsheimDirectorJun 2023
Paul V. MeisterDirectorJun 2023
Todd R. NelsonDirectorJun 2023
William F. SniderDirectorJun 2023